15996060||tx|S1|text|0|138|Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
[ Sex (NN, sex) hormone (NN, hormone) concentrations (NNS, concentration)  {NP} ]
[ in (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ with (IN, with)  {PP} ]
[ rheumatoid (JJ, rheumatoid) arthritis (NN, arthritis)  {NP} ]
[ are (VBP, be) not (RB, not) normalized (VBN, normalize)  {VP} ]
[ during (IN, during)  {PP} ]
[ 12 (CD, 12) weeks (NNS, week)  {NP} ]
[ of (IN, of)  {PP} ]
[ anti-tumor (JJ, anti-tumor) necrosis (NN, necrosis) factor (NN, factor) therapy (NN, therapy)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S1|entity|C0036884|Gonadal Steroid Hormones|horm,phsu|Sex hormone|833.3333333333334|0|11
15996060||tx|S1|entity|C0086045|Mental concentration|menp|concentrations|833.3333333333334|12|26
15996060||tx|S1|entity|C0030705|Patients|podg|patients|833.3333333333334|30|38
15996060||tx|S1|entity|C0003873|Rheumatoid Arthritis|dsyn|rheumatoid arthritis|833.3333333333334|44|64
15996060||tx|S1|entity|C1518422|Negation|ftcn|not|833.3333333333334|69|72
15996060||tx|S1|entity|C0439230|week|tmco|weeks|833.3333333333334|94|99
15996060||tx|S1|entity|C0027651|Neoplasms|neop|tumor|833.3333333333334|108|113
15996060||tx|S1|entity|C0027540|Necrosis|ortf|necrosis|833.3333333333334|114|122
15996060||tx|S1|entity|C1521761|Factor|ftcn|factor|833.3333333333334|123|129
15996060||tx|S1|entity|C0087111|Therapeutic procedure|topp|therapy|833.3333333333334|130|137

15996060||tx|S2|text|139|315|OBJECTIVE: Androgens such as dehydroepiandrosterone sulfate (DHEAS) and testosterone are markedly lower in postmenopausal women with rheumatoid arthritis (RA) than in controls.
[ OBJECTIVE (NN, objective)  {NP} ]
[ : (:, :)  {:} ]
[ Androgens (NNS, androgen)  {NP} ]
[ such (JJ, such) as (IN, as)  {PP} ]
[ dehydroepiandrosterone (NN, dehydroepiandrosterone) sulfate (NN, sulfate) ( (-LRB-, () DHEAS (NN, dhea) ) (-RRB-, )) and (CC, and) testosterone (NN, testosterone)  {NP} ]
[ are (VBP, be)  {VP} ]
[ markedly (RB, markedly) lower (JJR, lower)  {ADVP} ]
[ in (IN, in)  {PP} ]
[ postmenopausal (JJ, postmenopausal) women (NNS, woman)  {NP} ]
[ with (IN, with)  {PP} ]
[ rheumatoid (JJ, rheumatoid) arthritis (NN, arthritis) ( (-LRB-, () RA (NN, ra) ) (-RRB-, )) than (IN, than)  {NP} ]
[ in (IN, in)  {PP} ]
[ controls (NNS, control)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S2|entity|C0018017|objective (goal)|inpr|OBJECTIVE|833.3333333333334|139|148
15996060||tx|S2|entity|C0002844|Androgens|horm,phsu|Androgens|833.3333333333334|150|159
15996060||tx|S2|entity|C0057277|Dehydroepiandrosterone Sulfate|bacs,orch,phsu|dehydroepiandrosterone sulfate|833.3333333333334|168|198
15996060||tx|S2|entity|C0011185|prasterone|horm,orch,phsu|DHEAS|833.3333333333334|200|205
15996060||tx|S2|entity|C1515981|And|idcn|and|833.3333333333334|207|210
15996060||tx|S2|entity|C0039601|Testosterone|horm,orch,phsu|testosterone|833.3333333333334|211|223
15996060||tx|S2|entity|C0522501|Massive|qlco|markedly|833.3333333333334|228|236
15996060||tx|S2|entity|C1548802|Body Site Modifier - Lower|blor|lower|833.3333333333334|237|242
15996060||tx|S2|entity|C0232970|Postmenopausal state|fndg|postmenopausal|833.3333333333334|246|260
15996060||tx|S2|entity|C0043210|Woman|popg|women|833.3333333333334|261|266
15996060||tx|S2|entity|C0003873|Rheumatoid Arthritis|dsyn|rheumatoid arthritis|833.3333333333334|272|292
15996060||tx|S2|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|294|296

15996060||tx|S3|text|316|417|In contrast, compared to controls, serum levels of estrogens are normal or elevated in women with RA.
[ In (IN, in)  {PP} ]
[ contrast (NN, contrast)  {NP} ]
[ , (,, ,)  {,} ]
[ compared (VBN, compare)  {PP} ]
[ to (TO, to)  {PP} ]
[ controls (NNS, control)  {NP} ]
[ , (,, ,)  {,} ]
[ serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ estrogens (NNS, estrogen)  {NP} ]
[ are (VBP, be)  {VP} ]
[ normal (JJ, normal) or (CC, or) elevated (JJ, elevated)  {ADJP} ]
[ in (IN, in)  {PP} ]
[ women (NNS, woman)  {NP} ]
[ with (IN, with)  {PP} ]
[ RA (NN, ra)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S3|entity|C0009924|Contrast Media|irda|contrast|833.3333333333334|319|327
15996060||tx|S3|entity|C0229671|Serum|bdsu|serum|833.3333333333334|351|356
15996060||tx|S3|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|357|363
15996060||tx|S3|entity|C0014939|Estrogens|horm,orch,phsu|estrogens|833.3333333333334|367|376
15996060||tx|S3|entity|C0205307|Normal|qlco|normal|833.3333333333334|381|387
15996060||tx|S3|entity|C0205250|High|qlco|elevated|833.3333333333334|391|399
15996060||tx|S3|entity|C0043210|Woman|popg|women|833.3333333333334|403|408
15996060||tx|S3|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|414|416

15996060||tx|S4|text|418|610|Since tumor necrosis factor (TNF) alters production of these hormones, we investigated changes of these hormones during anti-TNF antibody (anti-TNF) therapy with adalimumab in longstanding RA.
[ Since (IN, since)  {SBAR} ]
[ tumor (NN, tumor) necrosis (NN, necrosis) factor (NN, factor)  {NP} ]
[ ( (-LRB-, ()  {VP} ]
[ TNF (NN, tnf) ) (-RRB-, ))  {NP} ]
[ alters (VBZ, alter)  {VP} ]
[ production (NN, production)  {NP} ]
[ of (IN, of)  {PP} ]
[ these (DT, these) hormones (NNS, hormone)  {NP} ]
[ , (,, ,)  {,} ]
[ we (PRP, we)  {NP} ]
[ investigated (VBD, investigate)  {VP} ]
[ changes (NNS, change)  {NP} ]
[ of (IN, of)  {PP} ]
[ these (DT, these) hormones (NNS, hormone)  {NP} ]
[ during (IN, during)  {PP} ]
[ anti-TNF (JJ, anti-tnf) antibody (NN, antibody) ( (-LRB-, () anti-TNF (JJ, anti-tnf) ) (-RRB-, )) therapy (NN, therapy)  {NP} ]
[ with (IN, with)  {PP} ]
[ adalimumab (NN, adalimumab)  {NP} ]
[ in (IN, in)  {PP} ]
[ longstanding (JJ, longstanding) RA (NN, ra)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S4|entity|C1323304|tumor necrosis factor binding|moft|tumor necrosis factor|833.3333333333334|424|445
15996060||tx|S4|entity|7124562|TNF|Gene|TNF|1000|447|450
15996060||tx|S4|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|447|450
15996060||tx|S4|entity|C0033268|production|ocac|production|833.3333333333334|459|469
15996060||tx|S4|entity|C0039828|Theses|inpr|these|833.3333333333334|473|478
15996060||tx|S4|entity|C0019932|Hormones|horm|hormones|833.3333333333334|479|487
15996060||tx|S4|entity|C1292732|Investigates|ftcn|investigated|833.3333333333334|492|504
15996060||tx|S4|entity|C0392747|Changing|ftcn|changes|833.3333333333334|505|512
15996060||tx|S4|entity|C0039828|Theses|inpr|these|833.3333333333334|516|521
15996060||tx|S4|entity|C0019932|Hormones|horm|hormones|833.3333333333334|522|530
15996060||tx|S4|entity|C0347984|During|tmco|during|833.3333333333334|531|537
15996060||tx|S4|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|543|546
15996060||tx|S4|entity|C0003241|Antibodies|imft,aapp|antibody|833.3333333333334|547|555
15996060||tx|S4|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|562|565
15996060||tx|S4|entity|C0087111|Therapeutic procedure|topp|therapy|833.3333333333334|567|574
15996060||tx|S4|entity|C1122087|adalimumab|imft,aapp,phsu|adalimumab|833.3333333333334|580|590
15996060||tx|S4|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|607|609

15996060||tx|S5|text|611|922|METHODS: In this longitudinal anti-TNF therapy study in 13 patients with long-standing RA without prior prednisolone (7 infusions of anti-TNF: Week 0, 2, 4, 6, 8, 10, and 12), we measured serum concentrations of interleukin 6 (IL-6), androstenedione, DHEA, DHEAS, free testosterone, estrone, and 17ss-estradiol.
[ METHODS (NNS, method)  {NP} ]
[ : (:, :)  {:} ]
[ In (IN, in)  {PP} ]
[ this (DT, this) longitudinal (JJ, longitudinal) anti-TNF (JJ, anti-tnf) therapy (NN, therapy) study (NN, study)  {NP} ]
[ in (IN, in)  {PP} ]
[ 13 (CD, 13) patients (NNS, patient)  {NP} ]
[ with (IN, with)  {PP} ]
[ long-standing (JJ, long-standing) RA (NN, ra)  {NP} ]
[ without (IN, without)  {PP} ]
[ prior (JJ, prior) prednisolone (NN, prednisolone) ( (-LRB-, () 7 (CD, 7) infusions (NNS, infusion)  {NP} ]
[ of (IN, of)  {PP} ]
[ anti-TNF (JJ, anti-tnf)  {NP} ]
[ : (:, :)  {:} ]
[ Week (NN, week) 0 (CD, 0) , (,, ,) 2 (CD, 2) , (,, ,) 4 (CD, 4) , (,, ,) 6 (CD, 6) , (,, ,) 8 (CD, 8) , (,, ,) 10 (CD, 10)  {NP} ]
[ , (,, ,)  {,} ]
[ and (CC, and)  {CC} ]
[ 12 (CD, 12) ) (-RRB-, ))  {NP} ]
[ , (,, ,)  {,} ]
[ we (PRP, we)  {NP} ]
[ measured (VBD, measure)  {VP} ]
[ serum (NN, serum) concentrations (NNS, concentration)  {NP} ]
[ of (IN, of)  {PP} ]
[ interleukin (NN, interleukin) 6 (CD, 6) ( (-LRB-, () IL-6 (NN, il-6) ) (-RRB-, )) , (,, ,) androstenedione (NN, androstenedione) , (,, ,) DHEA (NN, dhea) , (,, ,) DHEAS (NN, dhea) , (,, ,) free (JJ, free) testosterone (NN, testosterone)  {NP} ]
[ , (,, ,)  {,} ]
[ estrone (NN, estrone)  {NP} ]
[ , (,, ,)  {,} ]
[ and (CC, and)  {CC} ]
[ 17ss-estradiol (NN, 17ss-estradiol)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S5|entity|C0025664|Methods aspects|ftcn|METHODS|833.3333333333334|611|618
15996060||tx|S5|entity|C1080058|This (eukaryote)|euka|this|833.3333333333334|623|627
15996060||tx|S5|entity|C0205127|Longitudinal|spco|longitudinal|833.3333333333334|628|640
15996060||tx|S5|entity|C0279936|tumor necrosis factor therapy|topp|TNF therapy|833.3333333333334|646|657
15996060||tx|S5|entity|C2603343|Study|resa|study|833.3333333333334|658|663
15996060||tx|S5|entity|C0030705|Patients|podg|patients|833.3333333333334|670|678
15996060||tx|S5|entity|C0332287|In addition to|ftcn|with|833.3333333333334|679|683
15996060||tx|S5|entity|C0205166|Long|qlco|long|833.3333333333334|684|688
15996060||tx|S5|entity|C0231472|Standing position|spco|standing|833.3333333333334|689|697
15996060||tx|S5|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|698|700
15996060||tx|S5|entity|C0332288|Without|qlco|without|833.3333333333334|701|708
15996060||tx|S5|entity|C0332152|Before|tmco|prior|833.3333333333334|709|714
15996060||tx|S5|entity|C0032950|prednisolone|orch,phsu|prednisolone|833.3333333333334|715|727
15996060||tx|S5|entity|C0574032|Infusion procedures|topp|infusions|833.3333333333334|731|740
15996060||tx|S5|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|749|752
15996060||tx|S5|entity|C0439230|week|tmco|Week|833.3333333333334|754|758
15996060||tx|S5|entity|C1515981|And|idcn|and|833.3333333333334|778|781
15996060||tx|S5|entity|C0444706|Measured|qlco|measured|833.3333333333334|790|798
15996060||tx|S5|entity|C0229671|Serum|bdsu|serum|833.3333333333334|799|804
15996060||tx|S5|entity|C0086045|Mental concentration|menp|concentrations|833.3333333333334|805|819
15996060||tx|S5|entity|C0021760|Interleukin-6|imft,aapp|interleukin 6|666.6666666666666|823|836
15996060||tx|S5|entity|C1698754|IL6 protein, human|bacs,aapp|IL-6|666.6666666666666|838|842
15996060||tx|S5|entity|C0002860|Androstenedione|horm,orch,phsu|androstenedione|833.3333333333334|845|860
15996060||tx|S5|entity|C0011185|prasterone|horm,orch,phsu|DHEA|833.3333333333334|862|866
15996060||tx|S5|entity|C0011185|prasterone|horm,orch,phsu|DHEAS|833.3333333333334|868|873
15996060||tx|S5|entity|C0443483|Free testosterone|horm,orch|free testosterone|833.3333333333334|875|892
15996060||tx|S5|entity|C0014942|Estrone|horm,orch,phsu|estrone|833.3333333333334|894|901
15996060||tx|S5|entity|C1515981|And|idcn|and|833.3333333333334|903|906
15996060||tx|S5|entity|C0014912|Estradiol|horm,orch,phsu|estradiol|833.3333333333334|912|921

15996060||tx|S6|text|923|1033|Levels of these hormones in patients were compared to serum levels of 31 age and sex matched healthy controls.
[ Levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ these (DT, these) hormones (NNS, hormone)  {NP} ]
[ in (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ were (VBD, be) compared (VBN, compare)  {VP} ]
[ to (TO, to)  {PP} ]
[ serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ 31 (CD, 31) age (NN, age) and (CC, and) sex (NN, sex)  {NP} ]
[ matched (VBD, match)  {VP} ]
[ healthy (JJ, healthy) controls (NNS, control)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S6|entity|C0441889|Levels (qualifier value)|qlco|Levels|833.3333333333334|923|929
15996060||tx|S6|entity|C0039828|Theses|inpr|these|833.3333333333334|933|938
15996060||tx|S6|entity|C0019932|Hormones|horm|hormones|833.3333333333334|939|947
15996060||tx|S6|entity|C0030705|Patients|podg|patients|833.3333333333334|951|959
15996060||tx|S6|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|983|989
15996060||tx|S6|entity|C0001779|Age|orga|age|833.3333333333334|996|999
15996060||tx|S6|entity|C1515981|And|idcn|and|833.3333333333334|1000|1003
15996060||tx|S6|entity|C1522384|sex|orga|sex|833.3333333333334|1004|1007
15996060||tx|S6|entity|C0150103|MATCHING|resa|matched|833.3333333333334|1008|1015
15996060||tx|S6|entity|C3898900|Healthy|qlco|healthy|833.3333333333334|1016|1023

15996060||tx|S7|text|1034|1200|RESULTS: Upon treatment with anti-TNF, there was an impressive decrease of clinical markers of inflammation, erythrocyte sedimentation rate, and serum levels of IL-6.
[ RESULTS (NNS, result)  {NP} ]
[ : (:, :)  {:} ]
[ Upon (IN, upon)  {PP} ]
[ treatment (NN, treatment)  {NP} ]
[ with (IN, with)  {PP} ]
[ anti-TNF (JJ, anti-tnf)  {NP} ]
[ , (,, ,)  {,} ]
[ there (EX, there)  {NP} ]
[ was (VBD, be)  {VP} ]
[ an (DT, a) impressive (JJ, impressive) decrease (NN, decrease)  {NP} ]
[ of (IN, of)  {PP} ]
[ clinical (JJ, clinical) markers (NNS, marker)  {NP} ]
[ of (IN, of)  {PP} ]
[ inflammation (NN, inflammation)  {NP} ]
[ , (,, ,)  {,} ]
[ erythrocyte (NN, erythrocyte) sedimentation (NN, sedimentation) rate (NN, rate)  {NP} ]
[ , (,, ,)  {,} ]
[ and (CC, and)  {CC} ]
[ serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ IL-6 (NN, il-6)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S7|entity|C0087111|Therapeutic procedure|topp|treatment|833.3333333333334|1048|1057
15996060||tx|S7|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|1068|1071
15996060||tx|S7|entity|C0547047|Decrease|qnco|decrease|833.3333333333334|1097|1105
15996060||tx|S7|entity|C0008963|Markers, Clinical|qlco|clinical markers|833.3333333333334|1109|1125
15996060||tx|S7|entity|C0021368|Inflammation|patf|inflammation|833.3333333333334|1129|1141
15996060||tx|S7|entity|C1619634|erythrocyte sedimentation rate result|lbtr|erythrocyte sedimentation rate|833.3333333333334|1143|1173
15996060||tx|S7|entity|C1515981|And|idcn|and|833.3333333333334|1175|1178
15996060||tx|S7|entity|C0229671|Serum|bdsu|serum|833.3333333333334|1179|1184
15996060||tx|S7|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|1185|1191

15996060||tx|S8|text|1201|1359|Serum levels of DHEAS and free testosterone were markedly lower at baseline in patients compared to controls, but this did not change during anti-TNF therapy.
[ Serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ DHEAS (NNP, DHEAS)  {NP} ]
[ and (CC, and)  {CC} ]
[ free (JJ, free) testosterone (NN, testosterone)  {NP} ]
[ were (VBD, be)  {VP} ]
[ markedly (RB, markedly) lower (JJR, lower)  {ADJP} ]
[ at (IN, at)  {PP} ]
[ baseline (NN, baseline)  {NP} ]
[ in (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ compared (VBN, compare)  {VP} ]
[ to (TO, to)  {PP} ]
[ controls (NNS, control)  {NP} ]
[ , (,, ,)  {,} ]
[ but (CC, but)  {CC} ]
[ this (DT, this)  {NP} ]
[ did (VBD, do) not (RB, not) change (VB, change)  {VP} ]
[ during (IN, during)  {PP} ]
[ anti-TNF (JJ, anti-tnf) therapy (NN, therapy)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S8|entity|C0229671|Serum|bdsu|Serum|833.3333333333334|1201|1206
15996060||tx|S8|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|1207|1213
15996060||tx|S8|entity|C0011185|prasterone|horm,orch,phsu|DHEAS|833.3333333333334|1217|1222
15996060||tx|S8|entity|C1515981|And|idcn|and|833.3333333333334|1223|1226
15996060||tx|S8|entity|C0443483|Free testosterone|horm,orch|free testosterone|833.3333333333334|1227|1244
15996060||tx|S8|entity|C0522501|Massive|qlco|markedly|833.3333333333334|1250|1258
15996060||tx|S8|entity|C1548802|Body Site Modifier - Lower|blor|lower|833.3333333333334|1259|1264
15996060||tx|S8|entity|C1442488|Baseline|qnco|baseline|833.3333333333334|1268|1276
15996060||tx|S8|entity|C0030705|Patients|podg|patients|833.3333333333334|1280|1288
15996060||tx|S8|entity|C0233535|Butting|mobd|but|833.3333333333334|1311|1314
15996060||tx|S8|entity|C1080058|This (eukaryote)|euka|this|833.3333333333334|1315|1319
15996060||tx|S8|entity|C1518422|Negation|ftcn|not|833.3333333333334|1324|1327
15996060||tx|S8|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|1347|1350
15996060||tx|S8|entity|C0087111|Therapeutic procedure|topp|therapy|833.3333333333334|1351|1358

15996060||tx|S9|text|1360|1536|Serum levels of DHEA and 17ss-estradiol were significantly elevated in patients compared to controls, but similarly, anti-TNF therapy did not change initially increased levels.
[ Serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ DHEA (NN, dhea) and (CC, and) 17ss-estradiol (NN, 17ss-estradiol)  {NP} ]
[ were (VBD, be)  {VP} ]
[ significantly (RB, significantly) elevated (JJ, elevated)  {ADJP} ]
[ in (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ compared (VBN, compare)  {VP} ]
[ to (TO, to)  {PP} ]
[ controls (NNS, control)  {NP} ]
[ , (,, ,)  {,} ]
[ but (CC, but)  {CC} ]
[ similarly (RB, similarly)  {ADVP} ]
[ , (,, ,)  {,} ]
[ anti-TNF (JJ, anti-tnf) therapy (NN, therapy)  {NP} ]
[ did (VBD, do) not (RB, not) change (VB, change)  {VP} ]
[ initially (RB, initially) increased (VBN, increase) levels (NNS, level)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S9|entity|C0229671|Serum|bdsu|Serum|833.3333333333334|1360|1365
15996060||tx|S9|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|1366|1372
15996060||tx|S9|entity|C0011185|prasterone|horm,orch,phsu|DHEA|833.3333333333334|1376|1380
15996060||tx|S9|entity|C1515981|And|idcn|and|833.3333333333334|1381|1384
15996060||tx|S9|entity|C0014912|Estradiol|horm,orch,phsu|estradiol|833.3333333333334|1390|1399
15996060||tx|S9|entity|C0030705|Patients|podg|patients|833.3333333333334|1431|1439
15996060||tx|S9|entity|C0233535|Butting|mobd|but|833.3333333333334|1462|1465
15996060||tx|S9|entity|C0279936|tumor necrosis factor therapy|topp|TNF therapy|833.3333333333334|1482|1493
15996060||tx|S9|entity|C1518422|Negation|ftcn|not|833.3333333333334|1498|1501
15996060||tx|S9|entity|C0205265|Initially|tmco|initially|833.3333333333334|1509|1518
15996060||tx|S9|entity|C0442805|Increase|ftcn|increased|833.3333333333334|1519|1528
15996060||tx|S9|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|1529|1535

15996060||tx|S10|text|1537|1708|Molar ratios of hormones, which reflect hormone shifts via converting enzymes, showed typical alterations at baseline, but did not change markedly during anti-TNF therapy.
[ Molar (JJ, molar) ratios (NNS, ratio)  {NP} ]
[ of (IN, of)  {PP} ]
[ hormones (NNS, hormone)  {NP} ]
[ , (,, ,)  {,} ]
[ which (WDT, which)  {NP} ]
[ reflect (VBP, reflect)  {VP} ]
[ hormone (NN, hormone) shifts (NNS, shift)  {NP} ]
[ via (IN, via)  {PP} ]
[ converting (VBG, convert) enzymes (NNS, enzyme)  {NP} ]
[ , (,, ,)  {,} ]
[ showed (VBD, show)  {VP} ]
[ typical (JJ, typical) alterations (NNS, alteration)  {NP} ]
[ at (IN, at)  {PP} ]
[ baseline (NN, baseline)  {NP} ]
[ , (,, ,)  {,} ]
[ but (CC, but)  {CC} ]
[ did (VBD, do) not (RB, not) change (VB, change)  {VP} ]
[ markedly (RB, markedly)  {ADVP} ]
[ during (IN, during)  {PP} ]
[ anti-TNF (JJ, anti-tnf) therapy (NN, therapy)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S10|entity|C0026367|Molar tooth|bpoc|Molar|833.3333333333334|1537|1542
15996060||tx|S10|entity|C0456603|Ratio|qnco|ratios|833.3333333333334|1543|1549
15996060||tx|S10|entity|C0019932|Hormones|horm|hormones|833.3333333333334|1553|1561
15996060||tx|S10|entity|C0019932|Hormones|horm|hormone|833.3333333333334|1577|1584
15996060||tx|S10|entity|C0333051|shift displacement|ftcn|shifts|833.3333333333334|1585|1591
15996060||tx|S10|entity|C0014442|Enzymes|enzy,aapp|enzymes|833.3333333333334|1607|1614
15996060||tx|S10|entity|C3538928|Usual|qlco|typical|833.3333333333334|1623|1630
15996060||tx|S10|entity|C1442488|Baseline|qnco|baseline|833.3333333333334|1646|1654
15996060||tx|S10|entity|C0233535|Butting|mobd|but|833.3333333333334|1656|1659
15996060||tx|S10|entity|C1518422|Negation|ftcn|not|833.3333333333334|1664|1667
15996060||tx|S10|entity|C0522501|Massive|qlco|markedly|833.3333333333334|1675|1683
15996060||tx|S10|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|1696|1699
15996060||tx|S10|entity|C0087111|Therapeutic procedure|topp|therapy|833.3333333333334|1700|1707

15996060||tx|S11|text|1709|1881|CONCLUSION: Longterm therapy with anti-TNF did not change altered serum levels of typical sex hormones in patients with RA, although baseline values were largely different.
[ CONCLUSION (NN, conclusion)  {NP} ]
[ : (:, :)  {:} ]
[ Longterm (NN, longterm) therapy (NN, therapy)  {NP} ]
[ with (IN, with)  {PP} ]
[ anti-TNF (JJ, anti-tnf)  {NP} ]
[ did (VBD, do) not (RB, not) change (VB, change)  {VP} ]
[ altered (JJ, altered) serum (NN, serum) levels (NNS, level)  {NP} ]
[ of (IN, of)  {PP} ]
[ typical (JJ, typical) sex (NN, sex) hormones (NNS, hormone)  {NP} ]
[ in (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ with (IN, with)  {PP} ]
[ RA (NN, ra)  {NP} ]
[ , (,, ,)  {,} ]
[ although (IN, although)  {SBAR} ]
[ baseline (NN, baseline) values (NNS, value)  {NP} ]
[ were (VBD, be)  {VP} ]
[ largely (RB, largely) different (JJ, different)  {ADJP} ]
[ . (., .)  {.} ]
15996060||tx|S11|entity|C1707478|Conclusion|idcn|CONCLUSION|833.3333333333334|1709|1719
15996060||tx|S11|entity|C0087111|Therapeutic procedure|topp|therapy|833.3333333333334|1730|1737
15996060||tx|S11|entity|C1448177|TNF protein, human|bacs,aapp|TNF|833.3333333333334|1748|1751
15996060||tx|S11|entity|C1518422|Negation|ftcn|not|833.3333333333334|1756|1759
15996060||tx|S11|entity|C0392747|Changing|ftcn|altered|833.3333333333334|1767|1774
15996060||tx|S11|entity|C0229671|Serum|bdsu|serum|833.3333333333334|1775|1780
15996060||tx|S11|entity|C0441889|Levels (qualifier value)|qlco|levels|833.3333333333334|1781|1787
15996060||tx|S11|entity|C3538928|Usual|qlco|typical|833.3333333333334|1791|1798
15996060||tx|S11|entity|C0036884|Gonadal Steroid Hormones|horm,phsu|sex hormones|833.3333333333334|1799|1811
15996060||tx|S11|entity|C0030705|Patients|podg|patients|833.3333333333334|1815|1823
15996060||tx|S11|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|1829|1831
15996060||tx|S11|entity|C1442488|Baseline|qnco|baseline|833.3333333333334|1842|1850
15996060||tx|S11|entity|C0042295|Values|qlco|values|833.3333333333334|1851|1857
15996060||tx|S11|entity|C1705242|Different|qlco|different|833.3333333333334|1871|1880

15996060||tx|S12|text|1882|2068|In patients with RA, this indicates that alterations of sex hormones and altered activity of respective converting enzymes are imprinted for a long-lasting period over at least 12 weeks.
[ In (IN, in)  {PP} ]
[ patients (NNS, patient)  {NP} ]
[ with (IN, with)  {PP} ]
[ RA (NN, ra)  {NP} ]
[ , (,, ,)  {,} ]
[ this (DT, this)  {NP} ]
[ indicates (VBZ, indicate)  {VP} ]
[ that (IN, that)  {SBAR} ]
[ alterations (NNS, alteration)  {NP} ]
[ of (IN, of)  {PP} ]
[ sex (NN, sex) hormones (NNS, hormone)  {NP} ]
[ and (CC, and)  {CC} ]
[ altered (JJ, altered) activity (NN, activity)  {NP} ]
[ of (IN, of)  {PP} ]
[ respective (JJ, respective) converting (VBG, convert) enzymes (NNS, enzyme)  {NP} ]
[ are (VBP, be) imprinted (VBN, imprint)  {VP} ]
[ for (IN, for)  {PP} ]
[ a (DT, a) long-lasting (JJ, long-lasting) period (NN, period)  {NP} ]
[ over (IN, over)  {PP} ]
[ at (IN, at) least (JJS, least) 12 (CD, 12) weeks (NNS, week)  {NP} ]
[ . (., .)  {.} ]
15996060||tx|S12|entity|C0030705|Patients|podg|patients|833.3333333333334|1885|1893
15996060||tx|S12|entity|C0003873|Rheumatoid Arthritis|dsyn|RA|833.3333333333334|1899|1901
15996060||tx|S12|entity|C1080058|This (eukaryote)|euka|this|833.3333333333334|1903|1907
15996060||tx|S12|entity|C0036884|Gonadal Steroid Hormones|horm,phsu|sex hormones|833.3333333333334|1938|1950
15996060||tx|S12|entity|C1515981|And|idcn|and|833.3333333333334|1951|1954
15996060||tx|S12|entity|C0441655|Activities|acty|activity|833.3333333333334|1963|1971
15996060||tx|S12|entity|C0014442|Enzymes|enzy,aapp|enzymes|833.3333333333334|1997|2004
15996060||tx|S12|entity|C0205166|Long|qlco|long|833.3333333333334|2025|2029
15996060||tx|S12|entity|C1948053|Period (temporal qualifier)|tmco|period|833.3333333333334|2038|2044
15996060||tx|S12|entity|C0439230|week|tmco|weeks|833.3333333333334|2062|2067

167592||tx|S1|text|0|117|Control of hepatic glycogen metabolism in the rhesus monkey: effect of glucose, insulin, and glucagon administration.
[ Control (NN, control)  {NP} ]
[ of (IN, of)  {PP} ]
[ hepatic (JJ, hepatic) glycogen (NN, glycogen) metabolism (NN, metabolism)  {NP} ]
[ in (IN, in)  {PP} ]
[ the (DT, the) rhesus (NN, rhesus) monkey (NN, monkey)  {NP} ]
[ : (:, :)  {:} ]
[ effect (NN, effect)  {NP} ]
[ of (IN, of)  {PP} ]
[ glucose (NN, glucose)  {NP} ]
[ , (,, ,)  {,} ]
[ insulin (NN, insulin)  {NP} ]
[ , (,, ,)  {,} ]
[ and (CC, and)  {CC} ]
[ glucagon (NN, glucagon) administration (NN, administration)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S1|entity|C2587213|Control function|ftcn|Control|1000.0|0|7
167592||tx|S1|entity|C0599784|glycogen metabolic process|moft|glycogen metabolism|833.3333333333334|19|38
167592||tx|S1|entity|0294|rhesus monkey|Species|rhesus monkey|1000|46|59
167592||tx|S1|entity|C0024400|Macaca mulatta|mamm|rhesus monkey|833.3333333333334|46|59
167592||tx|S1|entity|C2348382|Effect, Appearance|qlco|effect|833.3333333333334|61|67
167592||tx|S1|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|71|78
167592||tx|S1|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|80|87
167592||tx|S1|entity|C1515981|And|idcn|and|833.3333333333334|89|92
167592||tx|S1|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|93|101
167592||tx|S1|entity|C0001554|Administration occupational activities|ocac|administration|833.3333333333334|102|116

167592||tx|S2|text|118|308|The effects of intravenous glucose, insulin and glucagon admininistration on the hepatic glycogen synthase and glycogen phosphorylase systems were assessed in the anesthetized rhesus monkey.
[ The (DT, the) effects (NNS, effect)  {NP} ]
[ of (IN, of)  {PP} ]
[ intravenous (JJ, intravenous) glucose (NN, glucose) , (,, ,) insulin (NN, insulin) and (CC, and) glucagon (NN, glucagon) admininistration (NN, admininistration)  {NP} ]
[ on (IN, on)  {PP} ]
[ the (DT, the) hepatic (JJ, hepatic) glycogen (NN, glycogen) synthase (NN, synthase) and (CC, and) glycogen (NN, glycogen) phosphorylase (NN, phosphorylase) systems (NNS, system)  {NP} ]
[ were (VBD, be) assessed (VBN, assess)  {VP} ]
[ in (IN, in)  {PP} ]
[ the (DT, the) anesthetized (JJ, anesthetized) rhesus (NN, rhesus) monkey (NN, monkey)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S2|entity|C1280500|Effect|qlco|effects|833.3333333333334|122|129
167592||tx|S2|entity|C0348016|Intravenous|spco|intravenous|833.3333333333334|133|144
167592||tx|S2|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|145|152
167592||tx|S2|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|154|161
167592||tx|S2|entity|C1515981|And|idcn|and|833.3333333333334|162|165
167592||tx|S2|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|166|174
167592||tx|S2|entity|C0443502|Hepatic glycogen synthase|enzy,aapp|hepatic glycogen synthase|833.3333333333334|199|224
167592||tx|S2|entity|C1515981|And|idcn|and|833.3333333333334|225|228
167592||tx|S2|entity|C0917785|Glycogen Phosphorylase|enzy,aapp|glycogen phosphorylase|833.3333333333334|229|251
167592||tx|S2|entity|C1516048|Assessed|acty|assessed|833.3333333333334|265|273
167592||tx|S2|entity|C1720436|Under anesthesia|fndg|anesthetized|833.3333333333334|281|293
167592||tx|S2|entity|C0024400|Macaca mulatta|mamm|rhesus monkey|833.3333333333334|294|307

167592||tx|S3|text|309|452|Results were correlated with measurements of hepatic cyclic AMP (cAMP) concentrations and plasma glucose, insulin, and glucagon concentrations.
[ Results (NNS, result)  {NP} ]
[ were (VBD, be) correlated (VBN, correlate)  {VP} ]
[ with (IN, with)  {PP} ]
[ measurements (NNS, measurement)  {NP} ]
[ of (IN, of)  {PP} ]
[ hepatic (JJ, hepatic) cyclic (JJ, cyclic) AMP (NN, amp) ( (-LRB-, () cAMP (NN, camp) ) (-RRB-, )) concentrations (NNS, concentration) and (CC, and) plasma (NN, plasma) glucose (NN, glucose)  {NP} ]
[ , (,, ,)  {,} ]
[ insulin (NN, insulin)  {NP} ]
[ , (,, ,)  {,} ]
[ and (CC, and)  {CC} ]
[ glucagon (NN, glucagon) concentrations (NNS, concentration)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S3|entity|C0242485|Measurement|ftcn|measurements|833.3333333333334|338|350
167592||tx|S3|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|354|361
167592||tx|S3|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cyclic AMP|833.3333333333334|362|372
167592||tx|S3|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|374|378
167592||tx|S3|entity|C0086045|Mental concentration|menp|concentrations|833.3333333333334|380|394
167592||tx|S3|entity|C1515981|And|idcn|and|833.3333333333334|395|398
167592||tx|S3|entity|C0455280|Plasma glucose result|lbtr|plasma glucose|833.3333333333334|399|413
167592||tx|S3|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|415|422
167592||tx|S3|entity|C1515981|And|idcn|and|833.3333333333334|424|427
167592||tx|S3|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|428|436
167592||tx|S3|entity|C0086045|Mental concentration|menp|concentrations|833.3333333333334|437|451

167592||tx|S4|text|453|612|Both glucose and insulin administration promoted significant inactivation of phosphorylase by 1 min, which was followed by more gradual activation of synthase.
[ Both (DT, both) glucose (NN, glucose) and (CC, and) insulin (NN, insulin) administration (NN, administration)  {NP} ]
[ promoted (VBD, promote)  {VP} ]
[ significant (JJ, significant) inactivation (NN, inactivation)  {NP} ]
[ of (IN, of)  {PP} ]
[ phosphorylase (NN, phosphorylase)  {NP} ]
[ by (IN, by)  {PP} ]
[ 1 (CD, 1) min (NN, min)  {NP} ]
[ , (,, ,)  {,} ]
[ which (WDT, which)  {NP} ]
[ was (VBD, be) followed (VBN, follow)  {VP} ]
[ by (IN, by)  {PP} ]
[ more (JJR, more) gradual (JJ, gradual) activation (NN, activation)  {NP} ]
[ of (IN, of)  {PP} ]
[ synthase (NN, synthase)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S4|entity|C0238767|Bilateral|spco|Both|833.3333333333334|453|457
167592||tx|S4|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|458|465
167592||tx|S4|entity|C1515981|And|idcn|and|833.3333333333334|466|469
167592||tx|S4|entity|C0199782|Administration of insulin|topp|insulin administration|833.3333333333334|470|492
167592||tx|S4|entity|C0750502|Significant|idcn|significant|833.3333333333334|502|513
167592||tx|S4|entity|C0544461|inactivation|ftcn|inactivation|833.3333333333334|514|526
167592||tx|S4|entity|C0017916|Phosphorylases|enzy,aapp|phosphorylase|833.3333333333334|530|543
167592||tx|S4|entity|C0205172|More|qnco|more|833.3333333333334|576|580
167592||tx|S4|entity|C0439833|Gradual|qlco|gradual|833.3333333333334|581|588
167592||tx|S4|entity|C1879547|Activation action|acty|activation|833.3333333333334|589|599
167592||tx|S4|entity|C0132555|Nitric Oxide Synthase|enzy,aapp|synthase|833.3333333333334|603|611

167592||tx|S5|text|613|684|Neither glucose nor insulin caused significant changes in hepatic cAMP.
[ Neither (DT, neither) glucose (NN, glucose) nor (CC, nor) insulin (NN, insulin)  {NP} ]
[ caused (VBD, cause)  {VP} ]
[ significant (JJ, significant) changes (NNS, change)  {NP} ]
[ in (IN, in)  {PP} ]
[ hepatic (JJ, hepatic) cAMP (NN, camp)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S5|entity|C3274651|Neither Case or Control Status|qlco|Neither|833.3333333333334|613|620
167592||tx|S5|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|621|628
167592||tx|S5|entity|C0028609|Nucleolus Organizer Region|celc|nor|833.3333333333334|629|632
167592||tx|S5|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|633|640
167592||tx|S5|entity|C0750502|Significant|idcn|significant|833.3333333333334|648|659
167592||tx|S5|entity|C0443172|Changed status|qnco|changes|833.3333333333334|660|667
167592||tx|S5|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|671|678
167592||tx|S5|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|679|683

167592||tx|S6|text|685|922|Marked hyperglucagonemia resulting from insulin-induced hypoglycemia did not cause increases IN in hepatic cAMP, suggesting that the elevated insulin levels possibly inhibited glucagon action on the hepatic adenylate cyclase-cAMP system.
[ Marked (JJ, marked) hyperglucagonemia (NN, hyperglucagonemia)  {NP} ]
[ resulting (VBG, result)  {VP} ]
[ from (IN, from)  {PP} ]
[ insulin-induced (JJ, insulin-induced) hypoglycemia (NN, hypoglycemia)  {NP} ]
[ did (VBD, do) not (RB, not) cause (VB, cause)  {VP} ]
[ increases (NNS, increase)  {NP} ]
[ IN (IN, in)  {PP} ]
[ in (IN, in)  {PP} ]
[ hepatic (JJ, hepatic) cAMP (NN, camp)  {NP} ]
[ , (,, ,)  {,} ]
[ suggesting (VBG, suggest)  {VP} ]
[ that (IN, that)  {SBAR} ]
[ the (DT, the) elevated (JJ, elevated) insulin (NN, insulin) levels (NNS, level)  {NP} ]
[ possibly (RB, possibly)  {ADVP} ]
[ inhibited (VBD, inhibit)  {VP} ]
[ glucagon (NN, glucagon) action (NN, action)  {NP} ]
[ on (IN, on)  {PP} ]
[ the (DT, the) hepatic (JJ, hepatic) adenylate (NN, adenylate) cyclase-cAMP (NN, cyclase-camp) system (NN, system)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S6|entity|C1706089|Marked|qlco|Marked|833.3333333333334|685|691
167592||tx|S6|entity|C0342218|Excessive glucagon secretion|fndg|hyperglucagonemia|833.3333333333334|692|709
167592||tx|S6|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|725|732
167592||tx|S6|entity|C0205263|Induce (action)|ftcn|induced|833.3333333333334|733|740
167592||tx|S6|entity|C0020615|Hypoglycemia|dsyn|hypoglycemia|833.3333333333334|741|753
167592||tx|S6|entity|C1518422|Negation|ftcn|not|833.3333333333334|758|761
167592||tx|S6|entity|C0205217|Increased|qnco|increases|833.3333333333334|768|777
167592||tx|S6|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|784|791
167592||tx|S6|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|792|796
167592||tx|S6|entity|C4014870|Elevated insulin|fndg|elevated insulin|833.3333333333334|818|834
167592||tx|S6|entity|C2362652|Possible diagnosis|qlco|possibly|833.3333333333334|842|850
167592||tx|S6|entity|C0311403|inhibited|qlco|inhibited|833.3333333333334|851|860
167592||tx|S6|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|861|869
167592||tx|S6|entity|C0441472|Clinical action|ftcn|action|833.3333333333334|870|876
167592||tx|S6|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|884|891
167592||tx|S6|entity|C1382029|Adenylyl Cyclase 9|enzy,aapp|adenylate cyclase|833.3333333333334|892|909
167592||tx|S6|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|910|914
167592||tx|S6|entity|C1704459|Device Component System|medd|system|833.3333333333334|915|921

167592||tx|S7|text|923|1131|Glucagon administration caused large increases in hepatic cAMP and activation of phosphorylase within 1 min, followed by more gradual inactivation of synthase when it had been previously activated by glucose.
[ Glucagon (NNP, Glucagon) administration (NN, administration)  {NP} ]
[ caused (VBD, cause)  {VP} ]
[ large (JJ, large) increases (NNS, increase)  {NP} ]
[ in (IN, in)  {PP} ]
[ hepatic (JJ, hepatic) cAMP (NN, camp) and (CC, and) activation (NN, activation)  {NP} ]
[ of (IN, of)  {PP} ]
[ phosphorylase (NN, phosphorylase)  {NP} ]
[ within (IN, within)  {PP} ]
[ 1 (CD, 1) min (NN, min)  {NP} ]
[ , (,, ,)  {,} ]
[ followed (VBN, follow)  {VP} ]
[ by (IN, by)  {PP} ]
[ more (JJR, more) gradual (JJ, gradual) inactivation (NN, inactivation)  {NP} ]
[ of (IN, of)  {PP} ]
[ synthase (NN, synthase)  {NP} ]
[ when (WRB, when)  {ADVP} ]
[ it (PRP, it)  {NP} ]
[ had (VBD, have) been (VBN, be) previously (RB, previously) activated (VBN, activate)  {VP} ]
[ by (IN, by)  {PP} ]
[ glucose (NN, glucose)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S7|entity|C0017687|Glucagon|horm,aapp,phsu|Glucagon|833.3333333333334|923|931
167592||tx|S7|entity|C0001554|Administration occupational activities|ocac|administration|833.3333333333334|932|946
167592||tx|S7|entity|C0549177|Large|qnco|large|833.3333333333334|954|959
167592||tx|S7|entity|C0205217|Increased|qnco|increases|833.3333333333334|960|969
167592||tx|S7|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|973|980
167592||tx|S7|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|981|985
167592||tx|S7|entity|C1515981|And|idcn|and|833.3333333333334|986|989
167592||tx|S7|entity|C1879547|Activation action|acty|activation|833.3333333333334|990|1000
167592||tx|S7|entity|C0017916|Phosphorylases|enzy,aapp|phosphorylase|833.3333333333334|1004|1017
167592||tx|S7|entity|C0205172|More|qnco|more|833.3333333333334|1044|1048
167592||tx|S7|entity|C0439833|Gradual|qlco|gradual|833.3333333333334|1049|1056
167592||tx|S7|entity|C0544461|inactivation|ftcn|inactivation|833.3333333333334|1057|1069
167592||tx|S7|entity|C0132555|Nitric Oxide Synthase|enzy,aapp|synthase|833.3333333333334|1073|1081
167592||tx|S7|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|1123|1130

167592||tx|S8|text|1132|1407|Concomitant glucose infusion, with resulting increased plasma insulin concentrations, markedly diminished the duration of hepatic cAMP elevations following glucagon adminstration, again suggesting an insulin inhibition of glucagon action on the hepatic adenylate-cAMP system.
[ Concomitant (JJ, concomitant) glucose (NN, glucose) infusion (NN, infusion)  {NP} ]
[ , (,, ,)  {,} ]
[ with (IN, with)  {PP} ]
[ resulting (VBG, result)  {VP} ]
[ increased (VBN, increase) plasma (NN, plasma) insulin (NN, insulin) concentrations (NNS, concentration)  {NP} ]
[ , (,, ,)  {,} ]
[ markedly (RB, markedly)  {ADVP} ]
[ diminished (VBD, diminish)  {VP} ]
[ the (DT, the) duration (NN, duration)  {NP} ]
[ of (IN, of)  {PP} ]
[ hepatic (JJ, hepatic) cAMP (NN, camp) elevations (NNS, elevation)  {NP} ]
[ following (VBG, follow)  {VP} ]
[ glucagon (NN, glucagon) adminstration (NN, adminstration)  {NP} ]
[ , (,, ,)  {,} ]
[ again (RB, again)  {ADVP} ]
[ suggesting (VBG, suggest)  {VP} ]
[ an (DT, a) insulin (NN, insulin) inhibition (NN, inhibition)  {NP} ]
[ of (IN, of)  {PP} ]
[ glucagon (NN, glucagon) action (NN, action)  {NP} ]
[ on (IN, on)  {PP} ]
[ the (DT, the) hepatic (JJ, hepatic) adenylate-cAMP (NN, adenylate-camp) system (NN, system)  {NP} ]
[ . (., .)  {.} ]
167592||tx|S8|entity|C0521115|Simultaneous|tmco|Concomitant|833.3333333333334|1132|1143
167592||tx|S8|entity|C0017725|Glucose|bacs,orch,phsu|glucose|833.3333333333334|1144|1151
167592||tx|S8|entity|C1827465|Infusion route|ftcn|infusion|833.3333333333334|1152|1160
167592||tx|S8|entity|C0205217|Increased|qnco|increased|833.3333333333334|1177|1186
167592||tx|S8|entity|C0857690|plasma insulin|lbpr|plasma insulin|833.3333333333334|1187|1201
167592||tx|S8|entity|C0086045|Mental concentration|menp|concentrations|833.3333333333334|1202|1216
167592||tx|S8|entity|C0522501|Massive|qlco|markedly|833.3333333333334|1218|1226
167592||tx|S8|entity|C0205216|Decreased|qnco|diminished|833.3333333333334|1227|1237
167592||tx|S8|entity|C0449238|Duration (temporal concept)|tmco|duration|833.3333333333334|1242|1250
167592||tx|S8|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|1254|1261
167592||tx|S8|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|1262|1266
167592||tx|S8|entity|C0702240|Elevation|spco|elevations|833.3333333333334|1267|1277
167592||tx|S8|entity|C0332282|Following|tmco|following|833.3333333333334|1278|1287
167592||tx|S8|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|1288|1296
167592||tx|S8|entity|C1533581|Recombinant Insulin|horm,aapp,phsu|insulin|833.3333333333334|1332|1339
167592||tx|S8|entity|C0021469|Metabolic Inhibition|moft|inhibition|833.3333333333334|1340|1350
167592||tx|S8|entity|C0017687|Glucagon|horm,aapp,phsu|glucagon|833.3333333333334|1354|1362
167592||tx|S8|entity|C0441472|Clinical action|ftcn|action|833.3333333333334|1363|1369
167592||tx|S8|entity|C0205054|Hepatic|blor|hepatic|833.3333333333334|1377|1384
167592||tx|S8|entity|C0597765|Adenylate|bacs,nnon|adenylate|833.3333333333334|1385|1394
167592||tx|S8|entity|C0001455|Cyclic AMP|bacs,nnon,phsu|cAMP|833.3333333333334|1395|1399
167592||tx|S8|entity|C1704459|Device Component System|medd|system|833.3333333333334|1400|1406

